The growing interest in potent weight management has resulted in considerable investigation into groundbreaking treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor stimulator, has shown positive results in medical trials, suggesting potential for significa